Showing 4461-4470 of 7767 results for "".
- DermOQ To Buy Skin Products's ECHO2 Plus Oxygen Facial Treatment Product Linehttps://practicaldermatology.com/news/dermoq-to-buy-skin-products-incs-echo2-plus-oxygen-facial-treatment-product-line/2460569/DermOQ Inc. is purchasing Skin Products Inc.’s ECHO2 Plus and Oxyceuticals oxygen facial treatment product lines. DermOQ offers its topical oxygen products under the brand names DermOQ Oxygen Lab and
- Eczema Missing Link Found: Researchers ID Protein that Triggers AD by Bacteriahttps://practicaldermatology.com/news/eczema-missing-link-found-researchers-id-protein-that-triggers-ad-by-bacteria/2460567/Second immunoglobulin-binding protein (Sbi) is a unique trigger of eczema by Staphylococcus aureus, according to research in the Journal of Allergy and Clinical Immunology. Sbi induces rapid release of Interleukin-33, a key component of the immune response in childhood ecz
- Coverage Update: Cigna to Cover Excimer Laser Treatment for Vitiligohttps://practicaldermatology.com/news/coverage-update-cigna-to-cover-excimer-laser-treatment-for-vitiligo/2460566/Cigna, a global health services company offering health, pharmacy, dental and Medicare plans to both individuals and businesses covering over 20 million people in the United States, has issued a new medical coverage policy for excimer laser therapy vitiligo. STRATA Skin Sciences, maker of the XTR
- Optical Coherence Tomography Plus AI Can Quickly and Accurately Monitor Hair Regrowthhttps://practicaldermatology.com/news/optical-coherence-tomography-plus-ai-can-quickly-and-accurately-monitor-hair-regrowth/2460564/Optical coherence tomography plus artificial intelligence methods can accurately and efficiently monitor hair growth therapies, suggests a
- Kerecis Scores DoD Grant to Develop, Test New Fish-skin Wound Treatment for Soldiershttps://practicaldermatology.com/news/kerecis-scores-dod-grant-to-develop-test-new-fish-skin-wound-treatment-for-soldiers/2460561/The U.S. Department of Defense (DoD) awarded a grant of almost $600,000 to Kerecis to test the company’s fish-skin technology to better stabilize battlefield wounds and provide a bacterial barrier for them during evacuation. The grant money will be disbursed to Kerecis over
- Vyne Therapeutics Announces Covered Status for Zilxi with Express Scriptshttps://practicaldermatology.com/news/yne-therapeutics-announces-covered-status-for-zilxi-with-express-scripts/2460557/Vyne Therapeutics Inc.’s Zilxi (minocycline) will be covered on Express Scripts' National Preferred, Flex, and Basic commercial formularies effective O
- Third RAD Conference Goes Virtual in Decemberhttps://practicaldermatology.com/news/third-rad-conference-goes-virtual-in-december/2460555/With a virtual format, the Third Revolutionizing Atopic Dermatitis (RAD) Conference is slated for December 13-14, 2020. Described by organizers as the first and only global, multidisciplinary conference dedicated to the discussion of evaluation and treatment options for atopi
- Brickell Biotech Initiates Phase 3 Trial of Sofpironium Bromide Gel for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-initiates-phase-3-trial-of-sofpironium-bromide-gel-for-hyperhidrosis/2460554/Brickell Biotech, Inc. has initiated its first pivotal US Phase 3 clinical study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis (“Cardigan I Study”). “This continues to be an exciting time for Brickell, with initiati
- NRS Survey Reveals Age Gap in Rosacea Treatmenthttps://practicaldermatology.com/news/nrs-survey-reveals-age-gap-in-rosacea-treatment/2460553/Most rosacea patients are satisfied with the oral and topical prescription therapies they are using to treat this disorder, but individuals 60 and older are more likely to use older treatments, rather than newer products that may more effectively target specific signs and symptoms, finds a new Na
- Zilxi from Vyne Therapeutics Now Availablehttps://practicaldermatology.com/news/zilxi-from-vyne-therapeutics-now-available/2460551/Zilxi™ (minocycline) topical foam, 1.5% is now available by prescription for the treatment of inflammatory lesions of rosacea in adults. Zilxi, from Vyne Therapeutics, Inc. is the first minocycline product of any form to be approved by the FDA for use in rosacea, a diverse skin co